RxDoctor Payments Data

Nicholas Zendler, DO

Neurology · Garden City, MINPI 1275897068

Payments from drug & device makers

$1,030in general payments, 2019–2025

Across 43 payments — averaging $23.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$184
  • Greenwich Biosciences, Inc.$174
  • Livanova USA, Inc.$171
  • Jazz Pharmaceuticals Inc.$123
  • Sunovion Pharmaceuticals Inc.$103
  • Amgen$83
  • plus $194 from 6 others

What the payments were for

  • Food & beverage$1,030100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,030 in reported general payments places this provider in the 45th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$40,969
Medicare patients
263
Services billed
483

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam96$133,710
Trokendi XrTopiramate13$85,086
EpidiolexCannabidiol (Cbd)29$83,067
XcopriCenobamate40$62,106
ZonisadeZonisamide27$45,050
Rufinamide20$40,319
Lacosamide350$36,613
Oxtellar XrOxcarbazepine14$33,933
KeppraLevetiracetam17$31,553
FelbatolFelbamate11$29,568
Clobazam222$25,710
FycompaPerampanel19$21,074
Lamotrigine ErLamotrigine53$20,558
NayzilamMidazolam24$20,047
Levetiracetam465$15,086

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Nayzilam, Vimpat$184$166,422131 claims
Supernus Pharmaceuticals, Inc.Trokendi Xr, Oxtellar Xr$55$119,01927 claims
SK Life Science, Inc.Xcopri$43$62,10640 claims
Upsher-smith Laboratories LLCTopiramate$23$2,136158 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 652 neurology providers in Michigan.

Other neurology in Garden City

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →